KPTI Karyopharm Therapeutics Inc.

11.33
-0.10  -1%
Previous Close 11.43
Open 11.34
Price To book 3.20
Market Cap 534083295
Shares 47,138,861
Volume 109,843
Short Ratio 8.44
Av. Daily Volume 206,280

SEC filingsSee all SEC filings

  1. 8-K - Current report 171133739
  2. 8-K - Current report 171094112
  3. 8-K - Current report 171081270
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014768
  5. 8-K - Current report 171013226

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data presented at ASH 2016.
Selinexor - SAIL
Acute myeloid leukemia (AML)
Phase 2 initiated April 2014. Interim data at ASCO 2015
Selinexor - (KING study)
Cancer - glioblastoma
Phase 2/3 trial initiated January 2016.Topline data for the Phase 2 portion released September 20, 2017 - PFS HR 0.60. Phase 3 data due 2019.
Selinexor - SEAL
Dedifferentiated liposarcoma
Phase 2b STORM Study Expansion data due April 2018.
Selinexor - STORM
Quadruple Refractory Multiple Myeloma
Phase 3 trial initiation announced June 7, 2017. Enrollment to be completed 2018 with data due 2019.
Selinexor - BOSTON
Multiple myeloma
Phase 2b additional interim data released June 23, 2017 at EHA. Final top-line data due 2H 2018.
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Data Safety Monitoring Board (DSMB) noted March 2, 2017 that trial will not meet primary endpoint.
Selinexor SOPRA
Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2 data presented at ASCO 2015. Phase 3 trial to be initiated late 2017.
Selinexor (SIGN Study)
Cancer - Advanced Gynecologic Malignancies (SIGN Study)
Phase 2 trial terminated.
Selinexor - SIRRT
Richter's transformation
Phase 2 trial terminated.
Selinexor - SHIP
Cancer - hormone-refractory prostate cancer (HRPC)

Latest News

  1. Karyopharm and Ono Pharmaceutical Co. Ltd. Sign Exclusive License Agreement to Develop and Commercialize Selinexor and KPT-8602 in Japan and Other Countries in Asia
  2. Edited Transcript of KPTI earnings conference call or presentation 8-Aug-17 12:30pm GMT
  3. Cancer Space Update: Mixed Week for Pfizer, Roche Falters
  4. Karyopharm's Liposarcoma Candidate Superior in Phase II Study
  5. Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma
  6. Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  7. Karyopharm Announces Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
  8. ETFs with exposure to Karyopharm Therapeutics, Inc. : August 31, 2017
  9. Karyopharm Announces the Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
  10. Karyopharm Therapeutics to Participate in Upcoming Investor Conferences
  11. Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : KPTI-US : August 28, 2017
  12. Karyopharm Therapeutics, Inc. :KPTI-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  13. Karyopharm Therapeutics posts 2Q loss
  14. Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress
  15. Investor Network: Karyopharm Therapeutics, Inc. to Host Earnings Call
  16. Karyopharm to Report Second Quarter 2017 Financial Results on August 8, 2017
  17. ETFs with exposure to Karyopharm Therapeutics, Inc. : July 24, 2017
  18. Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : July 19, 2017

SEC Filings

  1. 8-K - Current report 171133739
  2. 8-K - Current report 171094112
  3. 8-K - Current report 171081270
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014768
  5. 8-K - Current report 171013226
  6. 8-K - Current report 17927632
  7. 8-K - Current report 17916146
  8. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17895328
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17813959
  10. 8-K - Current report 17811780